Compare EOG Resources Inc (EOG) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs Medpace Holdings Inc — how do they compare? EOG Resources Inc trades at $149.5 (market cap $77.90B), while Medpace Holdings Inc trades at $605 (market cap $16.82B). The key difference: EOG Resources Inc is far larger — about 4.6× Medpace Holdings Inc's market cap, and EOG Resources Inc pays a 2.75% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold EOG Resources Inc for 59 Days and Medpace Holdings Inc for 14 Days on average.
| EOG | MEDP | |
|---|---|---|
Market Cap | $77.90B | $16.82B |
Volume | 2,930,386 | 223,093 |
Sector | Energy | Health |
52-Week High | $153.74 | $630.19 |
52-Week Low | $101.78 | $393.42 |
Typical Hold Time | 59 Days | 14 Days |
Enterprise Value | $81.24B | $16.44B |
Dividend Yield | 2.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $144.21, showing minimal daily movement with a slight decline of 0.05%. The stock maintains strong technical momentum with bullish moving averages and sits near pivot point resistance at $145. Fundamentally, EOG demonstrates robust profitability with 25.81% net income margin and attractive valuation metrics including a P/E of 11.56. Recent quarters show consistent earnings beats, with Q2 2026 EPS of $5.07 exceeding expectations. The company maintains solid cash flow generation despite increased capital expenditures.
EOG presents a compelling investment case with strong operational execution, disciplined capital allocation, and shareholder returns through dividends. Analyst consensus remains bullish with 59% buy ratings and $164.77 price target representing 14% upside. Key risks include oil price volatility and execution challenges in maintaining production growth. The combination of value pricing, consistent earnings performance, and positive technical momentum supports a constructive outlook for patient investors.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
